Rifaximin
Total Payments
$144,125
Transactions
13
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $144,125 | 13 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $144,125 | 13 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ACTA-RIFX-2015 | Teva Pharmaceuticals USA, Inc. | $144,125 | 0 |
Top Doctors Receiving Payments for Rifaximin
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Coral Gables, FL | $144,125 | 13 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $144,125
Product Information
- Type Drug
- Total Payments $144,125
- Total Doctors 0
- Transactions 13
About Rifaximin
Rifaximin is a drug associated with $144,125 in payments to 0 healthcare providers, recorded across 13 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $144,125 was paid across 13 transactions to 0 doctors.
The most common payment nature for Rifaximin is "Unspecified" ($144,125, 100.0% of total).
Rifaximin is associated with 1 research study, including "ACTA-RIFX-2015" ($144,125).